Nanostructured drug delivery for better management of tuberculosis

Journal of Controlled Release

Volumn 184, Issue 1, 2014, Pages 36-50

  Kaur, Indu Pal ^a   Singh, Harinder ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Antitubercular drugs (ATDs); Dose reduction; Nanostructured drug delivery; Polymers; Reduced side effects; Sustained release

Indexed keywords

BIOCHEMISTRY; BIOCOMPATIBILITY; CHEMOTHERAPY; DRUG DOSAGE; DRUG INTERACTIONS; LIPOSOMES; MICELLES; NANOPARTICLES; POLYMERS; TARGETED DRUG DELIVERY;

ANTI TUBERCULARS; DOSE REDUCTION; NANO-STRUCTURED; SIDE EFFECT; SUSTAINED RELEASE;

CONTROLLED DRUG DELIVERY;

CARBOMER; CLOFAZIMINE; DENDRIMER; ECONAZOLE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; LIPOSOME; NANOMATERIAL; NIOSOME; POLY(METHYL METHACRYLATE); POLYVINYLCHLORIDE; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; SOLID LIPID NANOPARTICLE; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG RESISTANT TUBERCULOSIS; DRUG SOLUBILITY; DRUG STABILITY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMPLANT; LATENT TUBERCULOSIS; MEDICATION COMPLIANCE; MICELLE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NANOEMULSION; NANOMEDICINE; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SECONDARY INFECTION; SUSTAINED DRUG RELEASE; TUBERCULOSIS; WORLD HEALTH ORGANIZATION; ANIMAL;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NANOSTRUCTURES; TUBERCULOSIS;

EID: 84899623067     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.04.009     Document Type: Review

References (176)

1. S.H. Kaufmann, and A.J. McMichael Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis Nat. Med. 11 2005 S33 S44
2. M.M. Gaspar, A. Cruz, A.G. Fraga, A.G. Castro, M.E.M. Cruz, and J. Pedrosa Developments on drug delivery systems for the treatment of mycobacterial infections Curr. Top. Med. Chem. 8 2008 579 591
3. C.D. Mitnick, S.C. Appleton, and S.S. Shin Epidemiology and treatment of multidrug resistant tuberculosis Semin. Respir. Care Med. 29 2008 499 524
4. T.S. Hauck, S. Giri, Y. Gao, and W.C. Chan Nanotechnology diagnostics for infectious diseases prevalent in developing countries Adv. Drug Deliv. Rev. 62 2010 438 448
5. T.R. Frieden, T.R. Sterling, S.S. Munsiff, C.J. Watt, and C. Dye Tuberculosis Lancet 362 2003 887 899
6. L.C. du Toit, V. Pillay, and M.P. Danckwerts Tuberculosis chemotherapy: current drug delivery approaches Respir. Res. 7 2006 118
7. WHO The health academy avoiding tuberculosis: Selfstudy Program on Tuberculosis downloaded from http://www.who.int/healthacademy/WHO-TB.pdf 2004 (on 29 December 2012)
8. I. Uhía, B. Galán, F.J. Medrano, and J.L. García Characterization of the KstR-dependent promoter of the gene for the first step of the cholesterol degradative pathway Microbiology 157 2011 2670 2680
9. J.A. Caminero, G. Sotgiu, A. Zumla, and G.B. Migliori Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis Lancet Infect. Dis. 10 2010 621 629
10. Z. Sun, J. Zhang, H. Song, X. Zhang, Y. Li, and M. Tian Concomitant increases in spectrum and level of drug resistance in Mycobacterium tuberculosis isolates Int. J. Tuberc. Lung Dis. 14 2010 1436 1441
11. Y.A. Skeiky, and J.C. Sadoff Advances in tuberculosis vaccine strategies Nat. Rev. Microbiol. 4 2006 469 476
12. R. Colebunders, and M.M. Lambert Management of co-infection with HIV and TB: improving tuberculosis control programmes and access to highly active antiretroviral treatment is crucial Br. Med. J. 324 2002 802 803
13. S.K. Sharma, A. Mohan, and T. Kadhiravan HIV-TB co-infection: epidemiology, diagnosis and management Indian J. Med. Res. 212 2005 550 567
14. WHO Tuberculosis and HIV/AIDS - Some Questions and Answers http://www.searo.who.int/en/Section10/Section18/Section356/section421-1624.htm 2006
15. P. Onyebujoh, A. Zumla, I. Ribeiro, R. Rustomjee, P. Mwaba, M. Gomes, and J.M. Grange Treatment of tuberculosis: present status and future prospects Bull. World Health Organ. 83 2005 857 865
16. WHO Treatment of tuberculosis: guidelines for national programmes 3rd Geneva World Health Organization, 2003 2003
17. B. Blomberg, S. Spinaci, B. Fourie, and R. Laing The rationale for recommending fixed dose combination tablets for treatment of tuberculosis Bull. World Health Organ. 79 2001 61 68
18. G.A. Ellard, and P.B. Fourie Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption Int. J. Tuberc. Lung Dis. 3 1999 S301 S308
19. Isoniazid Tuberculosis 88 2 2008 112 116
20. S.K. Jain, G. Lamichhane, S. Nimmagadda, M.G. Pomper, and W.R. Bishai Antibiotic treatment of tuberculosis: old problems, new solutions Microbe 3 2008 285 292
21. S.M. Moghimi, I.S. Muir, L. Illum, S.S. Davis, and V. Kolb-Bachofen Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum Biochim. Biophys. Acta 1179 1993 157 165
22. G.G. Gallo, and P. Radaelli K. Florey, Analytical Profile of Drug Substances vol. 5 1976 Academic Press New York 467 515
23. Rifampin Tuberculosis 88 2 2008 151 154
24. Ethambutol Tuberculosis 88 2 2008 102 105
25. S.K. Mehta, K.K. Bhasin, N. Mehta, and S. Dham Behavior of rifampicin in association with β-cyclodextrin in aqueous media: a spectroscopic and conductometric study Colloid Polym. Sci. 283 2005 532 538
26. Streptomycin Tuberculosis 88 2 2008 162 163
27. J.S. Mukherjee, M.L. Rich, A.R. Socci, J.K. Joseph, F.A. Viru, S.S. Shin, J.J. Furin, M.C. Becerra, D.J. Barry, J.Y. Kim, J. Bayona, P. Farmer, M.C. Smith Fawzi, and K.J. Seung Programmes and principles in treatment of multidrug-resistant tuberculosis Lancet 363 2004 474 481
28. I. Smith Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence Clin. Microbiol. Rev. 16 2003 463 496
29. L.T. Luyen, H.T.K. Huyen, T.V. Sang, and N.T.L. Huong Effects of isoniazid and pyrazinamide on bioavailability of rifampicin when co-administered rifampicin-isoniazid-pyrazinamide TTC Nghien Cuu Y Hoc 36 2005 12 17
30. M.C. Gohel, and K.G. Sarvaiya A novel solid dosage form of rifampicin and isoniazid with improved functionality AAPS PharmSciTech 8 2007 E133 E139
31. R.J. Prankerd, J.M. Walters, and J.H. Parnes Kinetics for degradation of rifampicin, an azomethine containing drug which exhibits reversible hydrolysis in acidic solutions Int. J. Pharm. 78 1992 59 67
32. T.T. Mariappan, and S. Singh Positioning of rifampicin in the Biopharmaceutics Classification System (BCS) Clin. Res. Regul. Aff. 23 2006 1 10
33. H. Singh, R. Bhandari, and I.P. Kaur Encapsulation of rifampicin in a solid lipid nanoparticulate system to limit its degradation and interaction with isoniazid at acidic pH Int. J. Pharm. 446 2013 106 111
34. C.J. Shishoo, S.A. Shah, I.S. Rathod, S.S. Savale, J.S. Kotecha, and P.B. Shah Stability of rifampicin in dissolution medium in presence of isoniazid Int. J. Pharm. 190 1999 109 123
35. S. Singh, T.T. Mariappan, N. Sharda, S. Kumar, and A.K. Chakraborti The reason for increase in decomposition of rifampicin in the presence of isoniazid under acid conditions Pharm. Pharmacol. Commun. 6 2000 405 410
36. S. Singh, T.T. Mariappan, N. Sharda, and B. Singh Degradation of rifampicin, isoniazid, and pyrazinamide from prepared mixtures and marketed single and combination products under acid conditions Pharm. Pharmacol. Commun. 6 2000 491 494
37. C.J. Shishoo, S.A. Shah, I.S. Rathod, S.S. Savale, and M.J. Vora Impaired bioavailability of rifampicin in presence of isoniazid from fixed dose combination (FDC) formulation Int. J. Pharm. 228 2001 53 67
38. R. Sankar, N. Sharda, and S. Singh Behaviour of decomposition of rifampicin in the presence of isoniazid in the pH range 1-3 Drug Dev. Ind. Pharm. 29 2003 733 738
39. A. Schatz, E. Bugie, and S.A. Waksman Streptomycin, a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria Clin. Orthop. Relat. Res. 2005 3 6
40. R. Pandey, and G.K. Khuller Polymer based drug delivery systems for mycobacterial infections Curr. Drug Deliv. 1 2004 195 201
41. R. Shegokar, L. Al Shaal, and K. Mitri Present status of nanoparticle research for treatment of tuberculosis J. Pharm. Pharm. Sci. 14 2011 100 116
42. W. Jiang, B.Y. Kim, J.T. Rutka, and W.C. Chan Advances and challenges of nanotechnology-based drug delivery systems Expert Opin. Drug Deliv. 4 2007 621 633
43. G. Muhuri, and T.K. Pal Computation of release kinetics of isoniazid microcapsules Boll. Chim. Farm. 130 1991 169 171
44. R. Jain, N.H. Shah, A.W. Malick, and C.T. Rhodes Controlled drug delivery by biodegradable poly(ester) devices: different preparative approaches Drug Dev. Ind. Pharm. 24 1998 703 727
45. P.R. Gangadharam, D.R. Ashtekar, D.C. Farhi, and D.L. Wise Sustained release of isoniazid in vivo from a single implant of a biodegradable polymer Tubercle 72 1991 115 122
46. S. Kailasam, D.L. Wise, and P.R. Gangadharam Bioavailability and chemotherapeutic activity of clofazimine against Mycobacterium avium complex infection in beige mice following a single implant of a biodegradable polymer J. Antimicrob. Chemother. 33 1994 273 279
47. P.R. Gangadharam, S. Kailasam, S. Srinivasan, and D.L. Wise Experimental chemotherapy of tuberculosis using single dose treatment with isoniazid in biodegradable polymers J. Antimicrob. Chemother. 33 1994 265 271
48. P.R. Gangadharam, N. Geeta, Y.Y. Hsu, and D.L. Wise Chemotherapy of tuberculosis in mice using single implants of isoniazid and pyrazinamide Int. J. Tuberc. Lung Dis. 3 1999 515 520
49. M. Dutt, and G.K. Khuller Poly (d, l-lactide-co-glycolide) microparticles as carriers for antimycobacterial drug rifampicin Indian J. Exp. Biol. 38 2000 887 894
50. M. Dutt, and G.K. Khuller Chemotherapy of Mycobacterium tuberculosis infections in mice by combination of isoniazid and rifampicin drugs entrapped in poly (d, l-lactide-co-glycolide) microparticles J. Antimicrob. Chemother. 47 2001 829 835
51. A.J. Khopade, and N.K. Jain A stable multiple emulsion system bearing isoniazid: preparation and characterization Drug Dev. Ind. Pharm. 24 1998 289 293
52. E.L.W. Barrow, G.A. Winchester, J.K. Staas, D.C. Quenelle, and W.W. Barrow Use of microsphere technology for sustained and targeted delivery of rifampin to Mycobacterium tuberculosis-infected mice Antimicrob. Agents Chemother. 42 1998 2682 2689
53. D.C. Quenelle, J.K. Staas, G.A. Winchester, E.L. Barrow, and W.W. Barrow Efficacy of microencapsulated rifampin in Mycobacterium tuberculosis-infected mice Antimicrob. Agents Chemother. 43 1999 1144 1151
54. Q. Ain, S. Sharma, S.K. Garg, and G.K. Khuller Role of poly [dl-lactide-co-glycolide] in development of a sustained oral delivery system for antitubercular drug(s) Int. J. Pharm. 239 2002 37 46
55. Q. Ain, S. Sharma, and G.K. Khuller Chemotherapeutic potential of orally administered poly(lactide-co-glycolide) microparticles containing isoniazid, rifampicin and pyrazinamide against experimental tuberculosis Antimicrob. Agents Chemother. 47 2003 3005 3007
56. http://www.usatoday.com/story/news/nation/2012/12/31/fda-tuberculosis- drug/1800367/ (Accessed on December, 2013)
57. P. Gao, X. Nie, M. Zou, Y. Shi, and G. Cheng Recent advances in materials for extended-release antibiotic delivery system J. Antibiot. (Tokyo) 64 2011 625 634
58. K.O. Kisich, S. Gelperina, M.P. Higgins, S. Wilson, E. Shipulo, and E. Oganesyan Encapsulation of moxifloxacin within poly (butylcyanoacrylate) nanoparticles enhances efficacy against intracellular Mycobacterium tuberculosis Int. J. Pharm. 345 2007 154 162
59. E.V. Shipulo, I.I. Lyubimov, O.O. Maksimenko, L.V. Vanchugova, E.A. Oganesyan, P.G. Sveshnikov, S.F. Biketov, E.S. Severin, L.B. Heifets, and S.E. Gelperina Development of a nanosomal formulation of moxifloxacin based on poly (butyl-2-cyanoacrylate) Pharm. Chem. J. 42 2008 145 149
60. R. Pandey, A. Sharma, A. Zahoor, S. Sharma, G.K. Khuller, and B. Prasad Poly (dl-lactide-coglycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis J. Antimicrob. Chemother. 52 2003 981 986
61. S.P. Vyas, M.E. Kannan, S. Jain, V. Mishra, and P. Singh Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages Int. J. Pharm. 269 2004 37 49
62. S.A. Wissing, O. Kayser, and R.H. Muller Solid lipid nanoparticles for parenteral drug delivery Adv. Drug Deliv. Rev. 56 2004 1257 1272
63. R. Pandey, and G.K. Khuller Solid lipid particle based inhalable sustained drug delivery system against experimental tuberculosis Tuberculosis 85 2005 227 234
64. W. Yan, M. Li, and H. Gao Polymeric micelle composed of PLA and chitosan as a drug carrier J. Polym. Res. 16 2009 11 18
65. M. Silva, E.I. Ferreira, C.Q.F. Leite, and D.N. Sato Preparation of polymeric micelles for use as carriers of tuberculostatic drugs Trop. J. Pharm. Res. 6 2007 815 824
66. M. Silva, A.S. Lara, C.Q.F. Leite, and E.I. Ferreira Potential tuberculostatic agents: micelle-forming copolymer poly(ethylene glycol)-poly(aspartic acid) prodrug with isoniazid Arch. Pharm. Pharm. Med. Chem. 334 2001 189 193
67. M. Silva, N.L. Ricelli, O. Seoud, C.S. Valentim, A.G. Ferreira, D.N. Sato, C.Q.F. Leite, and E.I. Ferreira Potential tuberculostatic agent: micelle-forming pyrazinamide prodrug Arch. Pharm. Chem. Life Sci. 339 2006 283 290
68. P.V. Kumar, H. Agashe, T. Dutta, and N.K. Jain PEGylated dendritic architecture for development of a prolonged drug delivery system for an antitubercular drug Curr. Drug Deliv. 4 2007 11 19
69. P.V. Kumar, A. Asthana, T. Dutta, and N.K. Jain Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers J. Drug Target. 14 2006 546 556
70. D.L. Clemens, B.Y. Lee, M. Xue, C.R. Thomas, H. Meng, D. Ferris, A.E. Nel, J.I. Zink, and M.A. Horwitz Targeted intracellular delivery of antituberculosis drugs to Mycobacterium tuberculosis-infected macrophages via functionalized mesoporous silica nanoparticles Antimicrob. Agents Chemother. 56 2012 2535 2545
71. G.K. Saraogi, P. Gupta, U.D. Gupta, N.K. Jain, and G.P. Agrawal Gelatin nanocarriers as potential vectors for effective management of tuberculosis Int. J. Pharm. 385 2010 143 149
72. Z. Ahmad, R. Pandey, S. Sharma, and G.K. Khuller Novel chemotherapy for tuberculosis: chemotherapeutic potential of econazole- and moxifloxacin-loaded PLG nanoparticles Int. J. Antimicrob. Agents 31 2008 142 146
73. S.K. Mehta, G. Kaur, and K.K. Bhasin Incorporation of antitubercular drug isoniazid in pharmaceutically accepted microemulsion: effect on microstructure and physical parameters Pharm. Res. 25 2008 227 236
74. K. Peters, S. Leitzke, J.E. Diederichs, K. Borner, H. Hahn, R.H. Müller, and S. Ehlers Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection J. Antimicrob. Chemother. 45 2000 77 83
75. E. Reverchon, I. De Marco, and G. Della Porta Rifampicin microparticles production by supercritical antisolvent precipitation Int. J. Pharm. 243 2002 83 91
76. E. Reverchon, and G. Della Porta Micronization of antibiotics by supercritical assisted atomization J. Supercrit. Fluids 2003 243 252
77. A. Sosnik, A.M. Carcaboso, R.J. Glisoni, M.A. Moretton, and D.A. Chiappetta New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery Adv. Drug Deliv. Rev. 62 2010 547 559
78. M. Dutt, and G.K. Khuller Therapeutic efficacy of poly (d, l-lactide-coglycolide) encapsulated antitubercular drugs against Mycobacterium tuberculosis infection induced in mice Antimicrob. Agents Chemother. 45 2001 363 366
79. M. Dutt, and G.K. Khuller Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in poly (dl-lactide-co-glycolide) microparticles J. Antimicrob. Chemother. 47 2001 829 835
80. D.A. Mitchison, and P.B. Fourie The near future: improving the activity of rifamycins and pyrazinamide Tuberculosis 90 2010 177 181
81. G. Scheuch, M.J. Kohlhaeufl, P. Brand, and R. Siekmeier Clinical perspectives on pulmonary systemic and macromolecular delivery Adv. Drug Deliv. Rev. 58 2006 996 1008
82. A.R. Mullaicharam, and R.S.R. Murthy Lung accumulation of niosome-entrapped rifampicin following intravenous and intratracheal administration in the rat J. Drug Deliv. Sci. Technol. 14 2004 99 104
83. R. Pandey, Z. Ahmed, S. Sharma, and G.K. Khuller Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis Tuberculosis 83 2003 373 378
84. Y.V. Anisimova, S.E. Gelperina, C.A. Peloquin, and I.B. Heifets Nanoparticles as antituberculosis drugs carriers: effect on activity against M. tuberculosis in human monocyte-derived macrophages J. Nanopart. Res. 2 2000 165 171
85. I.P. Kaur, H. Singh, Preparation of solid lipid nanoparticles of rifampicin to improve bioavailability and limiting drug interaction with isoniazid, India Patent, 17/01/2013, 2013.
86. I.P. Kaur, R. Bhandari, Solid lipid nanoparticles entrapping hydrophilic/amphiphilic drug and a process for preparing the same. PCT/IN2012/000154. Dated 5/03/2012
87. I.P. Kaur, M.K. Verma, Oral nanocolloidal aqueous dispersion (NCD) of streptomycin sulfate, India Patent, 3/10/2012.
88. M.A. Moretton, R.J. Glisoni, D.A. Chiappetta, and A. Sosnik Synthesis and characterization of amphiphilic poly/epsilon-caprolactone)-poly(ethyleneglycol) block copolymers. Optimization of the solubility and stability of rifampicin by means of encapsulation into polymeric micelles BIOOMAT 2009, I Workshop on Artificial Organs 2009 Biomaterials and Tissue Engineering, Latin American Society of Biomaterials, Tissue Engineering and Artificial Organs (SLABO) Rosario, Argentina
89. Z. Jiang, Y. You, X. Deng, and J. Hao Injectable hydrogels of poly(ε-caprolactone-coglycolide)-poly(ethylene glycol)-poly(ε- caprolactone-co glycolide) triblock copolymer aqueous solutions Polymer 48 2007 4786 4792
90. I.M. Orme Tuberculosis vaccines: current progress Drugs 65 2005 2437 2444
91. H.M. Vordermeier, M.A. Chambers, B.M. Buddle, J.M. Pollock, and R.G. Hewinson Progress in the development of vaccines and diagnostic reagents to control tuberculosis in cattle Vet. J. 171 2006 229 244
92. S. D'Souza, V. Rosseels, O. Denis, A. Tanghe, N. De Smet, F. Jurion, K. Palfliet, N. Castiglioni, A. Vanonckelen, C. Wheeler, and K. Huygen Improved tuberculosis DNA vaccines by formulation in cationic lipids Infect. Immun. 70 2002 3681 3688
93. S. Shafiq, F. Shakeel, S. Talegaonkar, F.J. Ahmad, R.K. Khar, and M. Ali Development and bioavailability assessment of ramipril nanoemulsion formulation Eur. J. Pharm. Biopharm. 66 2007 227 243
94. S. Shafiq, and F. Shakeel Effect of labrasol on self-nanoemulsification efficiency of ramipril nanoemulsion Pharmazie 64 2009 812 817
95. M. Ahmed, W. Ramadan, D. Rambhu, and F. Shakeel Potential of nanoemulsions for intravenous delivery of rifampicin Pharmazie 63 2008 806 811
96. S.K. Mehta, G. Kaur, and K.K. Bhasin Tween-embedded microemulsions - physicochemical and spectroscopic analysis for antitubercular drugs AAPS PharmSciTech 11 2010 143 153
97. S.P. Klemens, M.H. Cynamon, C.E. Swenson, and R.S. Ginsberg Liposome-encapsulated gentamicin therapy of Mycobacterium avium complex infection in beige mice Antimicrob. Agents Chemother. 34 1990 967 970
98. B.E. Rabinow Nanosuspensions in drug delivery Nat. Rev. Drug Discov. 3 2004 785 796
99. N. Duzgunes, D. Flasher, M.V. Reddy, J. Luna-Herrera, and P.R. Gangadharam Treatment of intracellular Mycobacterium avium complex infection by free and liposome-encapsulated sparfloxacin Antimicrob. Agents Chemother. 40 1996 2618 2621
100. S. Leitzke, W. Bucke, K. Borner, R. Muller, H. Hahn, and S. Ehlers Rationale for and efficacy of prolonged-interval treatment using liposome-encapsulated amikacin in experimental Mycobacterium avium infection Antimicrob. Agents Chemother. 42 1998 459 461
101. P. Deol, G.K. Khuller, and K. Joshi Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice Antimicrob. Agents Chemother. 41 1997 1211 1214
102. P. Deol, and G.K. Khuller Lung specific liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice Biochem. Biophys. Acta 1334 1997 161 172
103. R.T. Mehta, A. Keyhani, T.J. McQueen, B. Rosenbaum, K.V. Rolston, and J.J. Tarrand In vitro activities of free and liposomal drugs against Mycobacterium avium-M. intracellulare complex and Mycobacterium tuberculosis Antimicrob. Agents Chemother. 37 1999 2584 2587
104. L.B. Adams, I. Sinha, S.G. Franzblau, J.L. Krahenbuhl, and R.T. Mehta Effective treatment of acute and chronic murine tuberculosis with liposome encapsulated clofazimine Antimicrob. Agents Chemother. 43 1999 1638 1643
105. M.S. El-Ridy, D.M. Mostafa, A. Shehab, E.A. Nasr, and S. Abd El-Alim Biological evaluation of pyrazinamide liposomes for treatment of Mycobacterium tuberculosis Int. J. Pharm. 330 2007 82 88
106. M.M. Gaspar, A. Cruz, A.F. Penha, J. Reymao, A.C. Sousa, C.V. Eleuterio, S.A. Domingues, A.G. Fraga, A.L. Filho, M.E. Cruz, and J. Pedrosa Rifabutin encapsulated in liposomes exhibits increased therapeutic activity in a model of disseminated tuberculosis Int. J. Antimicrob. Agents 31 2008 37 45
107. M. Smola, T. Vandamme, and A. Sokolowski Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases Int. J. Nanomedicine 3 2008 1 9
108. C.P. Jain, and S.P. Vyas Preparation and characterization of niosomes containing rifampicin for lung targeting J. Microencapsul. 12 1995 401 407
109. C.P. Jain, S.P. Vyas, and V.K. Dixit Niosomal system for delivery of rifampicin to lymphatics Indian J. Pharm. Sci. 68 2006 575 578
110. G. Singh, H.K. Raghuvanshi, A. Anand, R. Pundir, and H. Dwivedi Targeted delivery of rifampicin by niosomal drug delivery system JPR 3 2010 1152 1154
111. R. Karki, G.C. Mamatha, G. Subramanya, and N. Udupa Preparation, characterization and tissue disposition of niosomes containing isoniazid Rasayan J. Chem. 2 2008 224 227
112. N. Tsapis, D. Bennett, K. O'Driscoll, K. Shea, M.M. Lipp, K. Fu, R.W. Clarke, D. Deaver, D. Yamins, J. Wright, C.A. Peloquin, D.A. Weitz, and D.A. Edwards Direct lung delivery of para-aminosalicylic acid by aerosol particles Tuberculosis 83 2003 379 385
113. P.K. Gaur, S. Mishra, V.B. Gupta, M.S. Rathod, S. Purohit, and B.A. Savla Targeted drug delivery of rifampicin to the lungs: formulation, characterization, and stability studies of preformed aerosolized liposome and in situ formed aerosolized liposome Drug Dev. Ind. Pharm. 36 2010 638 646
114. L. Garcia-Contreras, J. Fiegel, M.J. Telko, K. Elbert, A. Hawi, M. Thomas, J. VerBerkmoes, W.A. Germishuizen, P.B. Fourie, A.J. Hickey, and D. Edwards Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model Antimicrob. Agents Chemother. 51 2007 2830 2836
115. L. Brannon-Peppas Recent advances on the use of biodegradable microparticles and nanoparticles in controlled drug delivery Int. J. Pharm. 116 1995 1 9
116. D.E. Owens III, and N.A. Peppas Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles Int. J. Pharm. 307 2006 93 102
117. B. Semete In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems Nanomed. Nanotechnol. Biol. 6 2010 662 671
118. A. Sharma, R. Pandey, S. Sharma, and G.K. Khuller Chemotherapeutic efficacy of poly (d, l-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental Int. J. Antimicrob. Agents 24 2004 599 604
119. A. Sharma, S. Sharma, and G.K. Khuller Lectin functionalized poly (lactide-coglycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis J. Antimicrob. Chemother. 54 2004 760 766
120. F. Gabor, E. Bogner, A. Weissenboeck, and M. Wirth The lectin-cell interaction and its implications to intestinal lectin-mediated drug delivery Adv. Drug Delivery Rev. 56 2004 459 480
121. B.J. Johnson, L.G. Bekker, R. Rickman, S. Brown, M. Lesser, S. Ress, P. Willcox, L. Steyn, and G. Kaplan rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo Tuber. Lung Dis. 78 1997 195 203
122. K. Ohashi, T. Kabasawa, T. Ozeki, and H. Okada One step preparation of rifampicin/poly (lactic-coglycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis J. Control. Release 135 2009 19 24
123. R. Pandey, and G.K. Khuller Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model J. Antimicrob. Chemother. 54 2004 266 268
124. A. Zahoor, R. Pandey, S. Sharma, and G.K. Khuller Pharmacokinetic and pharmacodynamic behavior of antitubercular drugs encapsulated in alginate nanoparticles at two doses Int. J. Antimicrob. Agents 27 2006 409 416
125. L.C. du Toit, V. Pillay, Y.E. Choonara, and S.E. Iyuke Formulation and evaluation of a salted-out isoniazid-loaded nanosystem AAPS PharmSciTech 9 2008 174 181
126. R. Pandey, and G.K. Khuller Oral nanoparticle-based antituberculosis drug delivery to the brain in an experimental model J. Antimicrob. Chemother. 57 2006 146 1152
127. H. Swai, B. Semete, L. Kalombo, and P. Chelule Potential of treating tuberculosis with a polymeric nano-drug delivery system J. Control. Release 138 2008 49
128. V. Jenning, A. Lippacher, and S.H. Gohla Medium scale production of solid lipid nanoparticles (SLN) by high pressure homogenization J. Microencapsulation 19 2002 1 10
129. R.H. Muller, and C.M. Keck Challenges and solutions for the delivery of biotech drugs - a review of drug nanocrystal technology and lipid nanoparticles J. Biotechnol. 113 2004 151 170
130. P.M. Bummer Physical chemical considerations of lipid-based oral drug delivery-solid lipid nanoparticles Crit. Rev. Ther. Drug Carrier Syst. 21 2004 1 20
131. J.R. Koup, J. Williams-Warren, C.T. Viswanathan, A. Weber, and A.L. Smith Pharmacokinetics of rifampin in children II. Oral bioavailability Ther. Drug Monit. 8 1986 17 22
132. D.A. Chiappetta, and A. Sosnik Poly(ethylene oxide)-poly(propylene oxide) block copolymer micelles as drug delivery agents: improved hydrosolubility, stability and bioavailability of drugs Eur. J. Pharm. Biopharm. 66 2007 303 317
133. L. Chen, Z. Xie, J. Hu, X. Chen, and X. Jing Enantiomeric PLA-PEG block copolymers and their stereocomplex micelles used as rifampin delivery J. Nanoparticle Res. 9 2007 777 785
134. Y. Wu, M. Li, and H. Gao Polymeric micelle composed of PLA and chitosan as a drug carrier J. Polym. Res. 16 2009 11 18
135. Y. Jin, S. Chen, R. Xin, and Y. Zhou Monolayers of the lipid derivatives of isoniazid at the air/water interface and the formation of self-assembled nanostructures in water Colloids Surf. B: Biointerfaces 64 2008 229 235
136. D.A. Tomalia Birth of new molecular architecture: dendrimers as quantized building blocks for nanoscale synthetic polymer chemistry Prog. Polym. Sci. 30 2005 294 324
137. A.D. Emanuele, and D. Attwood Dendrimer-drug interactions Adv. Drug Deliv. Rev. 57 2005 2147 2162
138. R. Jevprasesphant, J. Penny, R. Jalal, D. Attwood, N.B. McKeown, and A.D. Emanuele The influence of surface modification on the cytotoxicity of PAMAM dendrimers Int. J. Pharm. 252 2003 263 266
139. M. Katti Pathogenesis, diagnosis, treatment, and outcome aspects of cerebral tuberculosis Med. Sci. Monit. 10 2004 215 229
140. V. Kakkar, and I.P. Kaur Evaluating potential of curcumin loaded solid lipid nanoparticles in aluminium induced behavioural, biochemical and histopathological alterations in mice brain Food Chem. Toxicol. 49 2011 2906 2913
141. V. Kakkar, A.K. Mishra, K. Chuttani, K. Chopra, and I.P. Kaur Delivery of sesamol loaded solid lipid nanoparticles to brain for menopause related emotional and cognitive central nervous system derangements Rejuvenation Res. 14 2011 597 604
142. V. Kakkar, S.K. Muppu, K. Chopra, and I.P. Kaur Curcumin loaded solid lipid nanoparticles: an efficient formulation approach for cerebral ischemic reperfusion injury in rats Eur. J. Pharm. Biopharm. 85 2013 339 345
143. G. Tosi, F. Rivasi, F. Gandolfi, L. Costantino, M.A. Vandelli, and F. Forni Conjugated poly (d, l-lactide-co-glycolide) for the preparation of in vivo detectable nanoparticles Biomaterials 26 2005 4189 4195
144. A.V. Kabanov, and E.V. Batrakova New technologies for drug delivery across the blood brain barrier Curr. Pharm. Des. 10 2004 1355 1363
145. R. Bhandari, and I.P. Kaur Pharmacokinetics, tissue distribution and relative bioavailability of isoniazid-solid lipid nanoparticles Int. J. Pharm. 441 2013 202 212
146. A.S. Ginsburg, J.H. Grosset, and W.R. Bishai Fluoroquinolones, tuberculosis, and resistance Lancet Infect. Dis. 3 2003 432 442
147. U.G. Lalloo, and A. Ambaram New antituberculous drugs in development Curr. HIV/AIDS Rep. 7 2010 143 151
148. E. Lopes, A.R. Pohlman, V. Bassani, and S.S. Guterres Polymeric colloidal systems containing ethionamide: preparation and physicochemical characterization Pharmazie 55 2000 527 530
149. G. Kumar, S. Sharma, N. Shafiq, P. Pandhi, G.K. Khuller, and S. Malhotra Pharmacokinetics and tissue distribution studies of orally administered nanoparticles encapsulated ethionamide used as potential drug delivery system in management of multi-drug resistant tuberculosis Drug Deliv. 18 2011 65 73
150. Z. Ahmad, S. Sharma, and G.K. Khuller Chemotherapeutic evaluation of alginate nanoparticle-encapsulated azole antifungal and antitubercular drugs against murine tuberculosis Nanomedicine 3 2007 239 243
151. Z. Ahmad, S. Sharma, and G.K. Khuller In vitro and ex vivo antimycobacterial potential of azole drugs against M. tuberculosis H37Rv FEMS Microbiol. Lett. 251 2005 19 22
152. Z. Ahmad, S. Sharma, and G.K. Khuller Azole antifungals as novel chemotherapeutic agents against murine tuberculosis FEMS Microbiol. Lett. 261 2006 181 186
153. Z. Ahmad, S. Sharma, and G.K. Khuller The potential of azole antifungals against latent/persistent tuberculosis FEMS Microbiol. Lett. 258 2006 200 203
154. E.L. Nuermberger, M.K. Spigelman, and Y.Y. Yew Current development and future prospects in chemotherapy of tuberculosis Respirology 15 2010 764 778
155. R. Pandey, and G.K. Khuller Nanoparticle-based oral drug delivery system for an injectable antibiotic-streptomycin. Evaluation in a murine tuberculosis model Chemotherapy 53 2007 437 441
156. C. Wang, and A.J. Hickey Isoxyl aerosols for tuberculosis treatment: preparation and characterization of particles AAPS PharmSciTech 11 2010 538 549
157. A. Kumar, G. Patel, and S.K. Menon Fullerene isoniazid conjugate - a tuberculostat with increased lipophilicity: synthesis and evaluation of antimycobacterial activity Chem. Biol. Drug Des. 73 2009 553 557
158. G.K. Khuller, and J.N. Verma Oral drug delivery system for azole, moxifloxacin and rifampicin 2010 (US20100310662)
159. M.A. Horwitz, and D.L. Clemens Antimicrobial for targeting intracellular pathogens 2000 (US6054133)
160. P.A. Dickinson, I.W. Kellaway, and S.W. Howells Particulate composition 2006 (US7018657 B2)
161. G.G. Barsegyan, S.G. Gumanov, L.N. Kryukov, S.L. Kuznetsov, T.A. Pomazkova, E.A. Vorontsov, and I.E. Zykova Rifabutin-based medicinal agent, nanoparticles-containing antimicrobial preparation and a method for the production thereof 2008 (WO2009002227 A1)
162. J. Schwarz, and M. Weisspapir Colloidal solid lipid vehicle for pharmaceutical use 2006 (US 20060222716 A1)
163. R. Becker, B. Kruss, R.H. Muller, and K. Peters Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution 1999 (US 5858410 A)
164. S.Y. Jeong, I.C. Kwon, and H. Chung Formulation solubilizing water-insoluble agents and preparation method thereof 2006 (US 6994862 B2)
165. N.M. Chandavarkar, K.C. Jindal, and R. Malayandi Nanodispersion of poorly water soluble drug(s) 2013 (WO 2013098841 A1)
166. C.E. Barry, and K. Duncan Tuberculosis-strategies towards antiinfectives for a chronic disease Drug Discov. Today 1 2004 491 496
167. A.J. Huh, and Y.J. Kwon Nanoantibiotics: a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era J. Control. Release 156 2011 128 145
168. A. Feklistov, V. Mekler, Q. Jiang, L.F. Westblade, H. Irschik, R. Jansen, A. Mustaev, S.A. Darst, and R.H. Ebright Rifamycins do not function by allosteric modulation of binding of Mg2+ to the RNA polymerase active center Proc. Natl Acad. Sci. U.S.A. 105 2008 14820 14825
169. H.F. Chambers L.L. Brunton, J.S. Lazo, K.L. Parker, Goodman and Gillman's the Pharmacological Basis of Therapeutics 2005 McGrawHill Publication 1219 1234
170. A.R. Martineau, P.M. Timms, G.H. Bothamley, Y. Hanifa, K. Islam, A.P. Claxton, G.E. Packe, J.C. Moore-Gillon, M. Darmalingam, R.N. Davidson, H.J. Milburn, L.V. Baker, R.D. Barker, N.J. Woodward, T.R. Venton, K.E. Barnes, C.J. Mullett, A.K. Coussens, C.M. Rutterford, C.A. Mein, G.R. Davies, R.J. Wilkinson, V. Nikolayevskyy, F.A. Drobniewski, S.M. Eldridge, and C.J. Griffiths High-dose vitamin D3 during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial Lancet 377 9761 2011 242 250
171. A. Crowle, and E. Ross Inhibition by retinoic acid of multiplication of virulent tubercle bacilli in cultured human macrophages Infect. Immun. 57 1989 840 844
172. P. Sasidharan, E. Rajeev, and V. Vijaykumari Tuberculosis and vitamin D deficiency J. Assoc. Physicians India 50 2002 554 558
173. A. Zittermann Vitamin D in preventive medicine: are we ignoring the evidence? Br. J. Nutr. 89 2003 552 572
174. P. Anand, D. Kaul, and M. Sharma Synergistic action of vitamin D and retinoic acid restricts invasion of macrophages by pathogenic mycobacteria J. Microbiol. Immunol. Infect. 2008 17 25
175. i.P. Kaur, M.K. Verma, A process for preparing solid lipid sustained release nanoparticles for delivery of vitamins, PCT/IB2013/050169 dated 9/1/2013.
176. M. Kumar, D. Singla, S. Singh, S. Sawhney, A.S. Chauhan, G. Singh, G. Sharma, and I.P. Kaur Development of a validated UPLC method for simultaneous estimation of both free and entrapped (in solid lipid nanoparticles) all-trans retinoic acid and cholecalciferol (vitamin D3) and its pharmacokinetic applicability in rats J. Pharm. Biomed. Anal. 91 2014 73 80